Study Hints of Rituximab MS BenefitMedPage TodayAmong 25 patients with secondary progressive MS treated with rituximab, nine showed decreases in disability and 12 appeared to stabilize after receiving at least two cycles of rituximab given every 3 mont…
CHICAGO, Jun 03, 2013 (BUSINESS WIRE) — — Rapid Onset of Clinical Activity … – MarketWatch (press release)
CHICAGO, Jun 03, 2013 (BUSINESS WIRE) — — Rapid Onset of Clinical Activity …MarketWatch (press release)An investigator-sponsored Phase 1b, open-label, dose-escalation study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combina…
New Meds, Medical Devices Up Heart Failure Outcomes – Monthly Prescribing Reference
|
New Meds, Medical Devices Up Heart Failure Outcomes
Monthly Prescribing Reference (HealthDay News) – Advances in medications and medical devices have improved overall survival and risk of sudden death over the past two decades for patients with advanced heart failure, according to a study published in the May issue of Circulation: … |
Fluoroquinolones May Double Acute Kidney Injury Risk – Medscape
MedscapeFluoroquinolones May Double Acute Kidney Injury RiskMedscapeThe authors excluded men with a history of chronic kidney disease or dialysis. They used logistic regression to calculate rate ratios, adjusting for fluoroquinolone indication, disease…
Partial nephrectomy's benefits unknown to some – ModernMedicine
|
Partial nephrectomy’s benefits unknown to some
ModernMedicine Radical nephrectomy has been shown to increase the risk of developing chronic kidney disease and associated cardiovascular complications when used to treat small renal tumors. Despite the risks, researchers from Memorial Sloan-Kettering Cancer Center … |
CELGENE CORPORATION : Study Evaluating REVLIMID® Combination … – 4-traders (press release)
|
CELGENE CORPORATION : Study Evaluating REVLIMID® Combination …
4-traders (press release) … today announced data from a study comparing melphalan, prednisone and REVLIMID (lenalidomide) (MPR) with high-dose chemotherapy and tandem autologous stem cell transplant (MEL200), as well as evaluating the effect of lenalidomide maintenance … |
Heart failure may provoke andropause symptoms – Healio
Heart failure may provoke andropause symptomsHealioAndropause symptoms affect nearly one-third of men with heart failure, despite their age. However, the development of heart failure provoked an acceleration of the natural aging process, thus leading t…
"Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013" Is … – SBWire (press release)
|
“Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013″ Is …
SBWire (press release) This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the … Remote people face heightened kidney riskNinemsn |
Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell … – Business Wire (press release)
|
Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell …
Business Wire (press release) … today announced data from a study comparing melphalan, prednisone and REVLIMID (lenalidomide) (MPR) with high-dose chemotherapy and tandem autologous stem cell transplant (MEL200), as well as evaluating the effect of lenalidomide maintenance … ASCO 2013 Multiple Myeloma Update – Day Two: Education SessionThe Myeloma Beacon |
Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell … – MarketWatch (press release)
|
Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell …
MarketWatch (press release) Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at ASCO. MEL200 demonstrated a longer median PFS and OS compared … ASCO 2013 Multiple Myeloma Update – Day Two: Education SessionThe Myeloma Beacon |